Global Attention Deficit Hyperactivity Disorder Market Insights, Epidemiology and Market Forecast 2016-2018 & 2027
DUBLIN, Jan. 24, 2019 /PRNewswire/ --
The "Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Attention Deficit Hyperactivity Disorder (ADHD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Attention Deficit Hyperactivity Disorder (ADHD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Attention Deficit Hyperactivity Disorder (ADHD) Epidemiology
According to ADHD Institute, meta-regression analyses have estimated the worldwide ADHD prevalence between 5.29% and 7.1% in children and adolescents, and at 3.4% (range 1.2-7.3%) in adults. The prevalence of Attention-deficit hyperactivity disorder (ADHD) is greater in males (60%) than females (40%).
Attention Deficit Hyperactivity Disorder (ADHD) Drug Chapters
This segment of the Attention Deficit Hyperactivity Disorder (ADHD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently available treatments can help reduce symptoms and improve functioning. Treatments include medications, psychotherapy, education or training, or a combination of treatments. The specific class of medications most commonly prescribed for Attention Deficit Hyperactivity Disorder (ADHD) include Stimulants. These Stimulant medications are found to be well-tolerated and they act quickly. Stimulant medications commonly prescribed for attention deficit disorder include methylphenidate (Ritalin, Concerta, Metadate, Methylin) and certain amphetamines (Dexedrine, Adderall etc.).
Other newer drugs approved for the treatment of Attention Deficit Disorder include Strattera (Eli Lilly) and Vyvanse (Shire). These drugs typically offer similar benefits to stimulants, but act in a different way on the brain. Antidepressants are also given in some cases. All these ADHD drugs however are related with certain side-effects such as decrease appetite, insomnia and decreased anxiety. Psychostimulants have also shown to be effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), but, their shorter duration of action highlights potential limitations.
Many players such as Sunovion, Orient Pharma, NeuroDerm and some other are involved in developing therapies for Attention Deficit Hyperactivity Disorder. Launch of emerging therapies such as Dasotraline (Sunovion) and ND0801 (NeuroDerm) etc. are expected to significantly change the treatment landscape of ADHD in the upcoming years.
Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
The Attention Deficit Hyperactivity Disorder (ADHD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the market of Attention Deficit Hyperactivity Disorder (ADHD) in 7MM is expected to change from 2016-2027.
Key Topics Covered:
1. Report Introduction
2. Attention Deficit Hyperactivity Disorder (ADHD) Market Overview at a Glance
2.1. 7 Major Market Size of Attention Deficit Hyperactivity Disorder (ADHD) in 2017
2.2. 7 Major Market Size of Attention Deficit Hyperactivity Disorder (ADHD) in 2027
3. Disease Background and Overview: Attention Deficit Hyperactivity Disorder (ADHD)
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)
4.3. 7MM Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)
4.4. 7MM Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)
4.5. Attention Deficit Hyperactivity Disorder (ADHD): Country- Wise Epidemiology
4.6. United States
4.7. EU-5
4.8. Assumptions and Rationale
5. Treatments & Medical Practices
5.1. Treatment Algorithm
5.2. Treatment Guidelines
6. Marketed drugs
6.1. Strattera: Eli Lilly
6.2. Vyvanse: Shire
7. Emerging Therapies
7.1. Key Cross Competition
7.2. Dasotraline: Sunovion
7.3. ND0801: NeuroDerm
8. Attention Deficit Hyperactivity Disorder (ADHD) Market Size
8.1. Key Findings
8.2. Total 7MM Attention Deficit Hyperactivity Disorder (ADHD) Market Analysis
8.3. Overview of Total Attention Deficit Hyperactivity Disorder (ADHD) Market
9. 7MM Attention Deficit Hyperactivity Disorder (ADHD): Country-Wise Market Analysis
Companies Mentioned
- Sunovion
- NeuroDerm
- Eli Lilly
- Shire
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/kxvsh6/global_attention?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article